Attovia Therapeutics

ATTO

Biotechnology · Healthcare

Price

$20.17

-0.21 (-1.03%)

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Attovia Therapeutics is a clinical-stage biotechnology company focused on developing new medicines to treat diseases. The company works on drug candidates that target the immune system, aiming to help patients with inflammatory and autoimmune conditions. It does not yet sell any approved products and is still in the research and development phase.

Attovia makes no revenue from product sales right now. Instead, it funds its operations through capital raises such as stock offerings and potentially partnership deals with larger pharmaceutical companies. Like most early-stage biotechs, it operates at a loss, reflected in its negative return on invested capital. The main risk the company faces is the high failure rate of clinical drug trials — if its lead drug candidates do not prove safe and effective in human studies, the company could run out of funding before reaching the market.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-20.0% YoY

Earnings declining

R&D Spend

$54M/ year

↑ Rising (+60% vs prior year)

>1,000% of revenue

222.9x the sector average (18%)

Investing heavily in future products and technology

Cash Runway

~22 months

$133M cash & investments

Quarterly Free Cash Flow

Adequate runway but may need to raise capital within 2 years

Heavy R&D investment

Attovia Therapeutics is putting 4011% of revenue into R&D and that number is rising. That's 222.9x the sector average.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

0.0% over 1y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 43.0M (2024) → 43.0M (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-14.8%

Weak — -14.8% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/1 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.01

Conservative — low debt load (0.01)

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial